Clonazepam

Therapeutic drug management in neurology and psychiatry settings, forensic toxicology investigations, pain management compliance programs, driving under the influence cases, and drugs of abuse screening all require detection of clonazepam, a long-acting benzodiazepine and Schedule IV controlled substance prescribed for seizure disorders, panic disorder, and anxiety, with its primary metabolite 7-aminoclonazepam serving as the key analytical target. UTAK’s benzodiazepines panels and dedicated single-analyte controls contain clonazepam in serum, whole blood, and urine matrices at multiple concentration levels, supporting both immunoassay screening and LC-MS/MS confirmatory methods used in clinical and forensic laboratory confirmation workflows. Stock and custom therapeutic drug monitoring QC solutions can incorporate related benzodiazepines such as alprazolam, diazepam, lorazepam, oxazepam, temazepam, midazolam, and other sedative-hypnotics to address your laboratory’s comprehensive benzodiazepine panel and pain management testing requirements.